Proteome Sciences expands into the US: New Facility to open in San Diego
Proteome Sciences plc is pleased to announce the expansion of its proteomics services into the United States of America (“US”).
Director/PDMR Shareholding
The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 12 and 13 April 2023 it purchased, respectively, 100,000 and 100,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,789,772 Ordinary Shares, equivalent to 22.97% of Proteome Sciences' total issued share capital.
Director/PDMR Shareholding
The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 4 and 5 April 2023 it purchased, respectively, 14,766 and 100,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,589,772 Ordinary Shares, equivalent to 22.89% of Proteome Sciences' total issued share capital.
Investor Presentation
Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Year End Results via the Investor Meet Company platform on 19 April 2023 at 10:00am BST.
Final results for the year ended 31 December 2022
The Company is pleased to announce its audited results for the year ended 31 December 2022.
Notice of Results
The Directors of Proteome Sciences look forward to updating shareholders on the Company’s performance, and on the outlook for 2023, at the time of announcing the 2022 full year results which are scheduled for announcement on Tuesday 4 April 2023.
Year End Trading Update
Proteome Sciences today provides an unaudited trading update for the financial year ended 31 December 2022.
Milestone Payment for TMT®/TMTpro™ Sales
The Company announces that pursuant to the exclusive licence and distributor agreement with Thermo Scientific, a cumulative sales milestone has been achieved by Thermo Scientific. Pursuant to the sales milestone, a milestone payment of £0.87m has been received by the Company and will be recognised in the 2022 financial year.++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++